PARKINSON DISEASE (Disorder)NCT07327645
The Effect of Proprioceptive Neuromuscular Facilitation on Trunk Mobility, Gait, Fear of Falling, and Quality of Life in Individuals Diagnosed With Parkinson's Disease
A study testing Proprioceptive Neuromuscular Facilitation (PNF) in people with PARKINSON DISEASE (Disorder) and Proprioceptive Neuromuscular Facilitation, run by Pamukkale University at 1 site in Turkey (Türkiye).
Trial summary
Parkinson's disease (PD) is a neurological disease that includes four main findings: resting tremor, bradykinesia, postural instability, and rigidity, in addition to many motor and non-motor symptoms . Read more about this study
- Who is it for?
- Ages 40 to 90 years
- Conditions the study is for
- PARKINSON DISEASE (Disorder), Proprioceptive Neuromuscular Facilitation, Fear of Falling
- What is being tested?
- Proprioceptive Neuromuscular Facilitation (PNF)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 4 Aug 2023to 30 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of Parkinson's Disease
- Agreement to participate in the study
- Age between 40-90 years
- Score of 21 or higher on the Montreal Cognitive Assessment Scale (MoCA)
- Hoehn-Yahr stage 1-3 (including 3)
Who cannot join
- • Refusal to participate in the study
- Having vision loss (can wear glasses or contact lenses)
- Having hearing loss (can wear a hearing aid)
- Being in Hoehn-Yahr stage 4-5
- Having accompanying neurological, orthopedic, and rheumatological diseases that prevent the performance of upper and lower extremity patterns.
Trial locations and contacts
1 site in 1 country.
About this study
Parkinson's disease (PD) is a neurological disease that includes four main findings: resting tremor, bradykinesia, postural instability, and rigidity, in addition to many motor and non-motor symptoms . PD, the most common form of Parkinsonism, is a chronic and progressive disease characterized by the loss of dopaminergic neurons located in the pars compacta region of the substantia nigra. Its degenerative prognosis, characterized by motor and non-motor problems such as bradykinesia, tremor, rigidity, abnormal postural control, gait disorders, depression, and cognitive impairment, makes the management of the disease difficult . The incidence of PD, which typically begins around the ages of 55-60, varies between 15-250/100,000. Studies conducted in Turkey have indicated an incidence of 202/100,000 . In PH, as the disease progresses, there is a decrease in trunk mobility, forward flexion posture, and consequently loss of postural stability, particularly due to axial rigidity. Trunk stiffness and decreased trunk muscle strength are greater in individuals with PH compared to healthy controls. It has been noted that the decrease in trunk mobility impairs both anterior-posterior and lateral balance, and that individuals with PH experiencing these symptoms have difficulty in timing and scaling effective corrective movements, resulting in an increased risk of falls.
Gait disorders are considered one of the most disabling aspects of PH and can strongly affect the patient's independence and quality of life. The underlying mechanisms of gait disorders are multifactorial and usually result from a multisystem lesion involving both dopaminergic and non-dopaminergic mechanisms . In addition to the clinical and functional effects of gait disorders, a more important issue is that this impairment in gait can result in falls and trauma. The fact that gait disorders are affected by the motor and non-motor symptoms of the disease, and that they are parallel to longevity and cognitive decline, increases the importance of treatment . Therefore, rehabilitation interventions aimed at treating or alleviating gait disorders should be one of the main focuses in individuals with PH .
Read more
Falls are one of the most important causes of morbidity for PH . Approximately 60% of PH patients fall at least once a year, and falls are recurrent in at least one-third of these patients . Falls, which occur as a result of various factors, lead to injuries, fear of falling, decreased independence, decreased quality of life, and increased healthcare costs in patients. Fear of falling leads to a decrease in the patient's self-confidence, withdrawal from social life, and the choice of an inactive lifestyle, resulting in an increased risk of falling. This situation becomes a vicious cycle over time. While 28-55% of elderly people living at home fear falling, this rate increases to 50-65% in those who have fallen before . In PH patients, this rate is much higher than in healthy controls and is important in predicting future falls . Therefore, it is stated that fear of falling should be included in the assessment and treatment programs of individuals with PH .
Quality of life is a multidimensional outcome measure consisting of three areas: physical, mental, and social, which are influenced by the individual's personal characteristics and environmental factors . Since chronic and progressive diseases affect every aspect of an individual's life, health-related quality of life is taken into consideration in the management of such diseases . PH affects the individual's ability to independently perform almost all daily living activities and causes negative consequences in quality of life. PH affects the individual not only physically, mentally, and socially, but also economically for the individual and their family due to the additional financial burden brought about by care and treatment costs . Therefore, the assessment of quality of life in individuals with PH is important and necessary .
Proprioceptive Neuromuscular Facilitation (PNF) is a method frequently used by physiotherapists to facilitate the emergence of motor responses through the stimulation of proprioceptors and to improve voluntary control in the central nervous system . The International PNF Association defines the PNF philosophy under 5 subheadings: positive approach (mental participation in therapy), functional approach (integrating real tasks from daily life), mobilizing reserves (radiation principle), holistic treatment of the individual, motor learning, and control principles using motor learning. PNF fully complies with the International Classification of Functioning, Disability and Health (ICF) because it addresses the relevant patient with their personal and environmental context components of deficiencies, activity limitations, and participation restrictions .
Read the detailed description
Parkinson's disease (PD) is a neurological disease that includes four main findings: resting tremor, bradykinesia, postural instability, and rigidity, in addition to many motor and non-motor symptoms . PD, the most common form of Parkinsonism, is a chronic and progressive disease characterized by the loss of dopaminergic neurons located in the pars compacta region of the substantia nigra. Its degenerative prognosis, characterized by motor and non-motor problems such as bradykinesia, tremor, rigidity, abnormal postural control, gait disorders, depression, and cognitive impairment, makes the management of the disease difficult . The incidence of PD, which typically begins around the ages of 55-60, varies between 15-250/100,000. Studies conducted in Turkey have indicated an incidence of 202/100,000 . In PH, as the disease progresses, there is a decrease in trunk mobility, forward flexion posture, and consequently loss of postural stability, particularly due to axial rigidity . Trunk stiffness and decreased trunk muscle strength are greater in individuals with PH compared to healthy controls. It has been noted that the decrease in trunk mobility impairs both anterior-posterior and lateral balance, and that individuals with PH experiencing these symptoms have difficulty in timing and scaling effective corrective movements, resulting in an increased risk of falls.
Gait disorders are considered one of the most disabling aspects of PH and can strongly affect the patient's independence and quality of life. The underlying mechanisms of gait disorders are multifactorial and usually result from a multisystem lesion involving both dopaminergic and non-dopaminergic mechanisms. In addition to the clinical and functional effects of gait disorders, a more important issue is that this impairment in gait can result in falls and trauma. The fact that gait disorders are affected by the motor and non-motor symptoms of the disease, and that they are parallel to longevity and cognitive decline, increases the importance of treatment . Therefore, rehabilitation interventions aimed at treating or alleviating gait disorders should be one of the main focuses in individuals with PH .
Falls are one of the most important causes of morbidity for PH . Approximately 60% of PH patients fall at least once a year, and falls are recurrent in at least one-third of these patients . Falls, which occur as a result of various factors, lead to injuries, fear of falling, decreased independence, decreased quality of life, and increased healthcare costs in patients. Fear of falling leads to a decrease in the patient's self-confidence, withdrawal from social life, and the choice of an inactive lifestyle, resulting in an increased risk of falling. This situation becomes a vicious cycle over time. While 28-55% of elderly people living at home fear falling, this rate increases to 50-65% in those who have fallen before . In PH patients, this rate is much higher than in healthy controls and is important in predicting future falls . Therefore, it is stated that fear of falling should be included in the assessment and treatment programs of individuals with PH.Quality of life is a multidimensional outcome measure consisting of three areas: physical, mental, and social, influenced by an individual's personal characteristics and environmental factors . Since chronic and progressive diseases affect every aspect of an individual's life, health-related quality of life is considered in the management of such diseases . PH affects an individual's ability to independently perform almost all daily living activities and leads to negative consequences in quality of life. PH affects the individual not only physically, mentally, and socially, but also economically for the individual and their family due to the additional financial burden of care and treatment costs . Therefore, evaluating the quality of life in individuals with PH is important and necessary.
Proprioceptive Neuromuscular Facilitation (PNF) is a method frequently used by physiotherapists to facilitate the emergence of a motor response through the stimulation of proprioceptors and to improve voluntary control in the central nervous system . The International PNF Association defines the PNF philosophy under 5 subheadings: positive approach (mental engagement in therapy), functional approach (integrating real tasks from daily life), mobilizing reserves (radiation principle), holistic treatment of the individual, motor learning, and control principles using motor learning. PNF fully complies with the International Classification of Functioning, Disability and Health (ICF) because it addresses the relevant patient along with their personal and environmental context components of deficiencies, activity limitations, and participation restrictions.Movements in the human body occur in oblique and rotational directions. In PNF, movements occur as a whole, rotationally and diagonally, and this common direction of movement is called a pattern. Applying PNF exercises in a patterned manner increases the effectiveness of the treatment . In PH, PNF can help individuals achieve efficient motor function and promote benefits related to physical aspects such as clinical condition, tremor, rigidity, bradykinesia, and balance disorders. Theoretical mechanisms for the effect of PNF include autogenic inhibition, reciprocal inhibition, and stress relaxation. These mechanisms could be used to treat rigidity and improve trunk mobility in PH, but there are very few studies reporting them in PH .
A meta-analysis examining PNF applications in individuals with PH included 6 studies. In these studies, PNF application was generally performed in combination with other methods (treadmill training, vibration, gait training), and the patterns were not applied in their pure form . This made it difficult to evaluate the effectiveness of PNF in isolation in individuals with PH. Furthermore, PNF applications in individuals with PH mostly involved lower extremity and pelvic patterns, often focusing on their effects on balance and gait parameters . However, the investigators anticipate that the combined use of upper and lower extremity patterns will have a positive effect on both trunk and gait and balance parameters, and the investigators believe that the PNF technique should be applied to the patient as a single exercise to determine its net effect in PH. The study's findings will contribute to determining the effectiveness of PNF in PH without the need for any additional methods or equipment, thus showcasing its applicability. Furthermore, a review of the literature reveals no studies examining the effects of PNF on trunk mobility, fear of falling, and quality of life. For all these reasons, the investigators believe that this planned study will both fill the gap in the literature and shed light on the treatment of PH patients for physiotherapists working in this field.
- Conditions
- PARKINSON DISEASE (Disorder), Proprioceptive Neuromuscular Facilitation, Fear of Falling, Gait Performance, Functional Abilities, Trunk Mobility
- Being tested
- Proprioceptive Neuromuscular Facilitation (PNF)
- Keywords
- Proprioceptive neuromuscular facilitation, parkinson disease, trunk mobility, Functional abilities, fear of falling, gait
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Proprioceptive Neuromuscular Facilitation (PNF)Other
Group 2 Treatment Program Warm-up exercises combined with breathing Scapula and pelvis PNF patterns Application of the D2 diagonal in the upper extremity and the D1 diagonal in the lower extremity with slow, opposing technique, without physiotherapist hand contact, accompanied by a metronome Cool-down exercises combined with breathing
Proprioceptive Neuromuscular Facilitation (PNF)Other
Group 1 Treatment Program Warm-up exercises combined with breathing Scapula and pelvis PNF patterns Application of the D2 diagonal in the upper extremity and the D1 diagonal in the lower extremity with slow, opposing technique, accompanied by physiotherapist's hand contact Cool-down exercises combined with breathing
Proprioceptive Neuromuscular Facilitation (PNF)Other
Group 3 Treatment Program Warm-up exercises combined with breathing Scapula and pelvis PNF patterns Application of the D2 diagonal in the upper extremity and the D1 diagonal in the lower extremity with slow, opposing technique, under physiotherapist observation, without physiotherapist contact or metronome Cool-down exercises combined with breathing
| Study group | Role | What they receive |
|---|---|---|
| Patients with PD-PNF-1 | Experimental | PNF-physiotherapist hand contact group Receives: Other: Proprioceptive Neuromuscular Facilitation (PNF) |
| Patients with PD-PNF-2 | Experimental | PNF-Metronom group Receives: Other: Proprioceptive Neuromuscular Facilitation (PNF) |
| Patients with PD-PNF-3 | Experimental | PNF-Action Observation Group Receives: Other: Proprioceptive Neuromuscular Facilitation (PNF) |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Modified Hoehn and Yahr Scale
Parkinson's Hoehn and Yahr Staging is a scale developed in 1967 by Margaret M. Hoehn and Melvin D. Yahr that examines the overall clinical condition of individuals with Parkinson's disease according to five stages. Advanced stage indicates an increased stage. It provides information about objective findings and functional impairment of the disease. Although initially designed as a 5-item scale with integer options from 1 to 5, some items with 0.5-point increments were later added.
Measured: 10 weeks after the start of treatment
Secondary outcomes (7)
The Movement Disorders Association-Unified Parkinson's Disease Rating Scale (MDS-UPRDS
The Movement Disorders Association-Unified Parkinson's Disease Rating Scale (MDS-UPRDS) is the most widely used of all clinical scales currently available for assessing motor impairment and disability in PD. The scale results in a score indicating the severity of the disease (35). It evaluates motor performance, mental and emotional status, and activities of daily living. In addition to these, the scale also assesses motor fluctuations, dyskinesias, and autonomic dysfunction that may occur as complications of levodopa treatment (36). The first section consists of 4 questions, the second section 13, and the third section 14. The fourth section is divided into three subsections (A-B-C). Sections A and B consist of 4 questions each, and section C consists of 3 questions. The higher the score, the greater the severity of the disease in PD.
Measured: 10 weeks after the start of treatment
Parkinson's Disease Questionnaire (PDQ-39):
Parkinson's Disease Questionnaire (PDQ-39): It is a valid, reliable and sensitive scale widely used to assess quality of life in individuals with PD. It consists of 39 questions in total, with sub-parameters including mobility, activity of daily living, emotional well-being, stigma, social support, cognition, communication and physical discomfort. The total score obtained from the scale ranges from 0 to 100. As the score increases, the quality of life deteriorates (37). A Turkish validity and reliability study of PHA-39 has been conducted.
Measured: 10 weeks after the start of treatment
Modified Fall Activity Scale (MFES):
Modified Fall Activity Scale (MFES): The Fall Activity Scale (FES) is the most widely used and best-known questionnaire for measuring fall-related confidence. The MFES aims to measure a person's perceived confidence while performing 10 defined daily living activities. The MFES is an expanded version developed by Hill et al., incorporating four additional outdoor activity tasks. With good scaling properties and test-retest reliability, the MFES is a clear and simple tool consisting of 14 questions used to assess fear of falling, scoring the activity in question on a scale of 0-10. The Turkish validity and reliability of the scale were established by Korkmaz et al.
Measured: 10 weeks after the start of treatment
Modified Schober test
This test was first described in 1937 by the German physician Paul Schober, and the method was modified by Macrae and Wright in 1969. In this test, while the person is in an upright position, the lumbosacral junction and 10 cm above it are marked. Then, a third mark is placed 5 cm below the lumbosacral junction. After anterior flexion performed as far forward as possible, the distance between the highest and lowest marks is measured with a tape measure or inclinometer. A distance of 4 cm or less indicates restricted lumbar movement. The modified Schober test is used in the assessment of spinal mobility.
Measured: 10 weeks after the start of treatment
Timed Up and Go Test (TUG)
The TUG, which includes walking and turning functions, has been shown to be highly reliable and valid for individuals with PH (28,29). It can accurately identify individuals with PH at risk of falling with 74% accuracy (43). The person undergoing the test sits in a chair of normal height. Upon the command "Start," the person is asked to stand up from the chair, walk 3 meters forward at a normal walking speed, and then return and sit back in the chair (43). It is generally administered twice, and the average time is recorded. The person is allowed to use an assistive device (if any), and this is noted (44). A time ≤10 seconds indicates that the patient walks independently and has a low risk of falling; a time >30 seconds indicates that the patient occasionally needs assistance and has a high risk of falling (45). The TUG will first be administered in isolation, and then repeated with a cognitive task (counting backward from 100 in increments of 3).
Measured: 10 weeks after the start of treatment
Spatio-Temporal Gait Analysis:
Gait analysis is the evaluation of neuromusculoskeletal system functions and the interpretation of results using numbers and graphs. While gait analysis can be performed visually, the human eye is insufficient to perceive movements within milliseconds, necessitating measurement with technological devices. Gait analysis devices make it possible to measure and evaluate force, moment, and muscle activity. Thanks to these systems, all stages of walking can be recorded completely, converted into numerical data, before/after comparisons can be made, and changes can be evaluated.
Measured: 10 weeks after the start of treatment
Statistical Analysis
Data were analyzed using SPSS 22.0 [IBM SPSS Statistics 22 software ® (Armonk, NY: IBM Corp.)]. Continuous variables were presented as mean ± standard deviation, median, and 25-75% interquartile range, while categorical variables were presented as number (n) and percentage (%). Differences between categorical variables were examined using Chi-Square analysis. Since parametric test assumptions were not met, the Wilcoxon signed-rank test was used to compare differences in the dependent group. The Kruskal-Wallis H test was used to compare differences in the independent group. The Mann-Whitney U test was used for pairwise comparisons of independent groups. Since there was more than one independent variable, partial eta-squared (partial η2) was used to calculate the effect strength of the independent variable on the dependent variable, controlling for the main and joint effects of other independent variables. A partial η2 value of 0.01 indicated low effect strength, 0.06 indicated average
Measured: 10 weeks after the start of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2026
- Study start4 Aug 2023
- Primary completion30 Jul 2025
- Study completion30 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for PARKINSON DISEASE (Disorder)Studies of the same condition, open and under way.
- More trials run by Pamukkale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Following a power analysis based on the reference study, a total of 42 individuals with PD were included in the study. Randomized according to age, gender, and Hoehn-Yahr level, the individuals were divided into three study groups. While all groups received PNF treatment, Group 1 performed PNF application with physical contact by the physiotherapist, Group 2 with metronome accompaniment, and Group 3 through action observation.
- Masking
- None (open label)
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pamukkale University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dudu ŞİMŞEK, Pamukkale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07327645
- Sponsor's protocol ID
- PamukkaleU-sımsek-DR-Tez-003
- Status last verified
- Jan 2026
- First submitted
- 25 Dec 2025
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Alexandre de Assis IS, Luvizutto GJ, Bruno ACM, Sande de Souza LAP. The Proprioceptive Neuromuscular Facilitation Concept in Parkinson Disease: A Systematic Review and Meta-Analysis. J Chiropr Med. 2020 Sep;19(3):181-187. doi: 10.1016/j.jcm.2020.07.003. Epub 2020 Dec 15.
PubMed 33362441
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Proprioceptive Neuromuscular Facilitation on Trunk Mobility, Gait, Fear of Falling, and Quality of Life in Individuals Diagnosed With Parkinson's Disease
- ClinicalTrials.gov ID
- NCT07327645
- Acronym / sponsor ID
- PamukkaleU-sımsek-DR-Tez-003
- Conditions
- PARKINSON DISEASE (Disorder), Proprioceptive Neuromuscular Facilitation, Fear of Falling, Gait Performance, Functional Abilities, Trunk Mobility
- Keywords
- Proprioceptive neuromuscular facilitation, parkinson disease, trunk mobility, Functional abilities, fear of falling, gait
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Pamukkale UniversityUniversity, hospital or other
- Study start
- 4 Aug 2023 (actual)
- Primary completion
- 30 Jul 2025 (actual)
- Study completion
- 30 Aug 2025 (actual)
- First posted
- 8 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Parkinson's disease (PD) is a neurological disease that includes four main findings: resting tremor, bradykinesia, postural instability, and rigidity, in addition to many motor and non-motor symptoms . PD, the most common form of Parkinsonism, is a chronic and progressive disease characterized by the loss of dopaminergic neurons located in the pars compacta region of the substantia nigra. Its degenerative prognosis, characterized by motor and non-motor problems such as bradykinesia, tremor, rigidity, abnormal postural control, gait disorders, depression, and cognitive impairment, makes the management of the disease difficult . The incidence of PD, which typically begins around the ages of 55-60, varies between 15-250/100,000. Studies conducted in Turkey have indicated an incidence of 202/100,000 . In PH, as the disease progresses, there is a decrease in trunk mobility, forward flexion posture, and consequently loss of postural stability, particularly due to axial rigidity. Trunk stiffness and decreased trunk muscle strength are greater in individuals with PH compared to healthy controls. It has been noted that the decrease in trunk mobility impairs both anterior-posterior and lateral balance, and that individuals with PH experiencing these symptoms have difficulty in timing and scaling effective corrective movements, resulting in an increased risk of falls.
Gait disorders are considered one of the most disabling aspects of PH and can strongly affect the patient's independence and quality of life. The underlying mechanisms of gait disorders are multifactorial and usually result from a multisystem lesion involving both dopaminergic and non-dopaminergic mechanisms . In addition to the clinical and functional effects of gait disorders, a more important issue is that this impairment in gait can result in falls and trauma. The fact that gait disorders are affected by the motor and non-motor symptoms of the disease, and that they are parallel to longevity and cognitive decline, increases the importance of treatment . Therefore, rehabilitation interventions aimed at treating or alleviating gait disorders should be one of the main focuses in individuals with PH .
Falls are one of the most important causes of morbidity for PH . Approximately 60% of PH patients fall at least once a year, and falls are recurrent in at least one-third of these patients . Falls, which occur as a result of various factors, lead to injuries, fear of falling, decreased independence, decreased quality of life, and increased healthcare costs in patients. Fear of falling leads to a decrease in the patient's self-confidence, withdrawal from social life, and the choice of an inactive lifestyle, resulting in an increased risk of falling. This situation becomes a vicious cycle over time. While 28-55% of elderly people living at home fear falling, this rate increases to 50-65% in those who have fallen before . In PH patients, this rate is much higher than in healthy controls and is important in predicting future falls . Therefore, it is stated that fear of falling should be included in the assessment and treatment programs of individuals with PH .
Quality of life is a multidimensional outcome measure consisting of three areas: physical, mental, and social, which are influenced by the individual's personal characteristics and environmental factors . Since chronic and progressive diseases affect every aspect of an individual's life, health-related quality of life is taken into consideration in the management of such diseases . PH affects the individual's ability to independently perform almost all daily living activities and causes negative consequences in quality of life. PH affects the individual not only physically, mentally, and socially, but also economically for the individual and their family due to the additional financial burden brought about by care and treatment costs . Therefore, the assessment of quality of life in individuals with PH is important and necessary .
Proprioceptive Neuromuscular Facilitation (PNF) is a method frequently used by physiotherapists to facilitate the emergence of motor responses through the stimulation of proprioceptors and to improve voluntary control in the central nervous system . The International PNF Association defines the PNF philosophy under 5 subheadings: positive approach (mental participation in therapy), functional approach (integrating real tasks from daily life), mobilizing reserves (radiation principle), holistic treatment of the individual, motor learning, and control principles using motor learning. PNF fully complies with the International Classification of Functioning, Disability and Health (ICF) because it addresses the relevant patient with their personal and environmental context components of deficiencies, activity limitations, and participation restrictions .
Detailed description
Parkinson's disease (PD) is a neurological disease that includes four main findings: resting tremor, bradykinesia, postural instability, and rigidity, in addition to many motor and non-motor symptoms . PD, the most common form of Parkinsonism, is a chronic and progressive disease characterized by the loss of dopaminergic neurons located in the pars compacta region of the substantia nigra. Its degenerative prognosis, characterized by motor and non-motor problems such as bradykinesia, tremor, rigidity, abnormal postural control, gait disorders, depression, and cognitive impairment, makes the management of the disease difficult . The incidence of PD, which typically begins around the ages of 55-60, varies between 15-250/100,000. Studies conducted in Turkey have indicated an incidence of 202/100,000 . In PH, as the disease progresses, there is a decrease in trunk mobility, forward flexion posture, and consequently loss of postural stability, particularly due to axial rigidity . Trunk stiffness and decreased trunk muscle strength are greater in individuals with PH compared to healthy controls. It has been noted that the decrease in trunk mobility impairs both anterior-posterior and lateral balance, and that individuals with PH experiencing these symptoms have difficulty in timing and scaling effective corrective movements, resulting in an increased risk of falls.
Gait disorders are considered one of the most disabling aspects of PH and can strongly affect the patient's independence and quality of life. The underlying mechanisms of gait disorders are multifactorial and usually result from a multisystem lesion involving both dopaminergic and non-dopaminergic mechanisms. In addition to the clinical and functional effects of gait disorders, a more important issue is that this impairment in gait can result in falls and trauma. The fact that gait disorders are affected by the motor and non-motor symptoms of the disease, and that they are parallel to longevity and cognitive decline, increases the importance of treatment . Therefore, rehabilitation interventions aimed at treating or alleviating gait disorders should be one of the main focuses in individuals with PH .
Falls are one of the most important causes of morbidity for PH . Approximately 60% of PH patients fall at least once a year, and falls are recurrent in at least one-third of these patients . Falls, which occur as a result of various factors, lead to injuries, fear of falling, decreased independence, decreased quality of life, and increased healthcare costs in patients. Fear of falling leads to a decrease in the patient's self-confidence, withdrawal from social life, and the choice of an inactive lifestyle, resulting in an increased risk of falling. This situation becomes a vicious cycle over time. While 28-55% of elderly people living at home fear falling, this rate increases to 50-65% in those who have fallen before . In PH patients, this rate is much higher than in healthy controls and is important in predicting future falls . Therefore, it is stated that fear of falling should be included in the assessment and treatment programs of individuals with PH.Quality of life is a multidimensional outcome measure consisting of three areas: physical, mental, and social, influenced by an individual's personal characteristics and environmental factors . Since chronic and progressive diseases affect every aspect of an individual's life, health-related quality of life is considered in the management of such diseases . PH affects an individual's ability to independently perform almost all daily living activities and leads to negative consequences in quality of life. PH affects the individual not only physically, mentally, and socially, but also economically for the individual and their family due to the additional financial burden of care and treatment costs . Therefore, evaluating the quality of life in individuals with PH is important and necessary.
Proprioceptive Neuromuscular Facilitation (PNF) is a method frequently used by physiotherapists to facilitate the emergence of a motor response through the stimulation of proprioceptors and to improve voluntary control in the central nervous system . The International PNF Association defines the PNF philosophy under 5 subheadings: positive approach (mental engagement in therapy), functional approach (integrating real tasks from daily life), mobilizing reserves (radiation principle), holistic treatment of the individual, motor learning, and control principles using motor learning. PNF fully complies with the International Classification of Functioning, Disability and Health (ICF) because it addresses the relevant patient along with their personal and environmental context components of deficiencies, activity limitations, and participation restrictions.Movements in the human body occur in oblique and rotational directions. In PNF, movements occur as a whole, rotationally and diagonally, and this common direction of movement is called a pattern. Applying PNF exercises in a patterned manner increases the effectiveness of the treatment . In PH, PNF can help individuals achieve efficient motor function and promote benefits related to physical aspects such as clinical condition, tremor, rigidity, bradykinesia, and balance disorders. Theoretical mechanisms for the effect of PNF include autogenic inhibition, reciprocal inhibition, and stress relaxation. These mechanisms could be used to treat rigidity and improve trunk mobility in PH, but there are very few studies reporting them in PH .
A meta-analysis examining PNF applications in individuals with PH included 6 studies. In these studies, PNF application was generally performed in combination with other methods (treadmill training, vibration, gait training), and the patterns were not applied in their pure form . This made it difficult to evaluate the effectiveness of PNF in isolation in individuals with PH. Furthermore, PNF applications in individuals with PH mostly involved lower extremity and pelvic patterns, often focusing on their effects on balance and gait parameters . However, the investigators anticipate that the combined use of upper and lower extremity patterns will have a positive effect on both trunk and gait and balance parameters, and the investigators believe that the PNF technique should be applied to the patient as a single exercise to determine its net effect in PH. The study's findings will contribute to determining the effectiveness of PNF in PH without the need for any additional methods or equipment, thus showcasing its applicability. Furthermore, a review of the literature reveals no studies examining the effects of PNF on trunk mobility, fear of falling, and quality of life. For all these reasons, the investigators believe that this planned study will both fill the gap in the literature and shed light on the treatment of PH patients for physiotherapists working in this field.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Following a power analysis based on the reference study, a total of 42 individuals with PD were included in the study. Randomized according to age, gender, and Hoehn-Yahr level, the individuals were divided into three study groups. While all groups received PNF treatment, Group 1 performed PNF application with physical contact by the physiotherapist, Group 2 with metronome accompaniment, and Group 3 through action observation.
| Arm | Type | Receives |
|---|---|---|
| Patients with PD-PNF-1 | Experimental | Other: Proprioceptive Neuromuscular Facilitation (PNF)PNF-physiotherapist hand contact group |
| Patients with PD-PNF-2 | Experimental | Other: Proprioceptive Neuromuscular Facilitation (PNF)PNF-Metronom group |
| Patients with PD-PNF-3 | Experimental | Other: Proprioceptive Neuromuscular Facilitation (PNF)PNF-Action Observation Group |
Who may qualify
- Ages
- 40 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of Parkinson's Disease
Key exclusion criteria (5 listed)
- • Refusal to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Proprioceptive Neuromuscular Facilitation (PNF)Group 2 Treatment Program Warm-up exercises combined with breathing Scapula and pelvis PNF patterns Application of the D2 diagonal in the upper extremity and the D1 diagonal in the lower extremity with slow, opposing technique, without physiotherapist hand contact, accompanied by a metronome Cool-down exercises combined with breathing | Other | Patients with PD-PNF-2 |
| Proprioceptive Neuromuscular Facilitation (PNF)Group 1 Treatment Program Warm-up exercises combined with breathing Scapula and pelvis PNF patterns Application of the D2 diagonal in the upper extremity and the D1 diagonal in the lower extremity with slow, opposing technique, accompanied by physiotherapist's hand contact Cool-down exercises combined with breathing | Other | Patients with PD-PNF-1 |
| Proprioceptive Neuromuscular Facilitation (PNF)Group 3 Treatment Program Warm-up exercises combined with breathing Scapula and pelvis PNF patterns Application of the D2 diagonal in the upper extremity and the D1 diagonal in the lower extremity with slow, opposing technique, under physiotherapist observation, without physiotherapist contact or metronome Cool-down exercises combined with breathing | Other | Patients with PD-PNF-3 |
Primary outcome
The Modified Hoehn and Yahr Scale
Time frame: 10 weeks after the start of treatment
Parkinson's Hoehn and Yahr Staging is a scale developed in 1967 by Margaret M. Hoehn and Melvin D. Yahr that examines the overall clinical condition of individuals with Parkinson's disease according to five stages. Advanced stage indicates an increased stage. It provides information about objective findings and functional impairment of the disease. Although initially designed as a 5-item scale with integer options from 1 to 5, some items with 0.5-point increments were later added.
7 secondary outcomes
The Movement Disorders Association-Unified Parkinson's Disease Rating Scale (MDS-UPRDS
Time frame: 10 weeks after the start of treatment
Parkinson's Disease Questionnaire (PDQ-39):
Time frame: 10 weeks after the start of treatment
Modified Fall Activity Scale (MFES):
Time frame: 10 weeks after the start of treatment
Modified Schober test
Time frame: 10 weeks after the start of treatment
Timed Up and Go Test (TUG)
Time frame: 10 weeks after the start of treatment
Spatio-Temporal Gait Analysis:
Time frame: 10 weeks after the start of treatment
Statistical Analysis
Time frame: 10 weeks after the start of treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Results publication: PubMed 33362441Alexandre de Assis IS, Luvizutto GJ, Bruno ACM, Sande de Souza LAP. The Proprioceptive Neuromuscular Facilitation Concept in Parkinson Disease: A Systematic Review and Meta-Analysis. J Chiropr Med. 2020 Sep;19(3):181-187. doi: 10.1016/j.jcm.2020.07.003. Epub 2020 Dec 15.
- Individual participant dataSharing planned: No
Related trials for PARKINSON DISEASE (Disorder)
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Proprioceptive Neuromuscular Facilitation (PNF) in people with PARKINSON DISEASE (Disorder) and Proprioceptive Neuromuscular Facilitation, run by Pamukkale University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Modified Hoehn and Yahr Scale (time frame: 10 weeks after the start of treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07327645, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026; AzTrials last refreshed its copy on 7 Nov 2026.